Exchange: NASDAQ·Updated 04:04 PM EST

STLN News

News
all
press releases
Starling Oncology, Inc. (STLN) delivered earnings and revenue surprises of -85.71% and +0.93%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Geron (GERN) delivered earnings and revenue surprises of +100.00% and +0.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ultragenyx (RARE) delivered earnings and revenue surprises of -0.87% and -6.11%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
STARLING ONCOLO (STLN) delivered earnings and revenue surprises of -14.29% and +5.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.